Biostate AI secures $12M in Series A funding led by Accel to enhance RNA sequencing services for precision medicine.
Biostate AI secures $12M in Series A funding led by Accel to enhance RNA sequencing services for precision medicine.
05/20/25, 12:33 PM
Location
houstonMoney raised
$12 million
Industry
biotechnology
Investors
Accel
Biostate AI has completed a $12M Series A funding round to advance RNA sequencing for molecular diagnostics. Led by Accel, the funding aims to revolutionize accessibility and integration of precision medicine. Co-founders Ashwin Gopinath and David Zhang focus on utilizing comprehensive RNA analyses. Their goal is to create predictive models that lead to personalized therapeutics.
Company Info
Location
houston, texas, united states
Additional Info
Biostate AI is a startup building generative AI that predicts the evolution of human disease and drug response based on RNA sequencing data. Its patented wetlab technologies, including BIRT, allow affordable and scalable collection of massive amounts of transcriptomic and genomic data. With sites in Houston, TX, Palo Alto, CA, Bangalore, India, and Shanghai, China, Biostate AI is a global company with collaborations with top hospitals, academic researchers, and biotech/biopharma companies. Biostate AI was founded by serial entrepreneurs and former professors David Zhang (Rice U.) and Ashwin Gopinath (MIT) and is backed by top investors and experts including Accel, Dario Amodei (Anthropic), Emily Leproust (Twist Biosciences), and Mike Schnall-Levin (10X Genomics).